20/20 Biolabs opened lower at $0.22, compared with its previous close of $0.22. In the last trading session, the stock traded between $0.19 and $0.22. It showed a downward intraday trend.
An investment of $100 made 1 year ago in 20/20 Biolabs is now worth
$ 0.86
Resulting in a loss of
$ 99.14 (99.14%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.02 (-8.85%)
Day High
$0.22
Day Low
$0.19
Day Open
$0.22
Prev Close
$0.22
Volume
2,45,599
1W Return
-10.09%
1M Return
-43.68%
3M Return
-53.30%
6M Return
-85.04%
1Y Return
-99.14%
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
4.72
PEG Ratio
-
ROE
-771.64%
ROCE
-209.91%
EPS (TTM)
-
1 Week
-10.09%
1 Month
-43.68%
3 Months
-53.30%
6 Months
-85.04%
9 Months
-99.14%
20/20 BioLabs reschedules investor webinar to 2 pm ET on Sept 2
20/20 BioLabs reschedules its Sept 2 investor webinar to 2:00 p.m. ET. OneTest revenue hit a record $0.7 million in Q2FY26, up 47.1% YoY. Gross margin expanded to 41.7% from 30.5% due to operating leverage. CEO Jonathan Cohen will discuss commercial strategy and regulatory path.
2mo ago20/20 Biolabs Q2 Results: EPS misses, revenue up 36%
20/20 Biolabs posted a wider quarterly loss of $(0.26) per share, significantly missing the $(0.06) estimate. Revenue grew 36.54% YoY to $730.571K but fell short of the $891.000K consensus, indicating margin pressure despite top-line expansion.
2mo ago20/20 BioLabs sets Aug 5 webinar on East Asia roll-up strategy
20/20 BioLabs will host an investor webinar on August 5, 2026, to discuss its East Asia business development tour and roll-up strategy. CEO Jonathan Cohen will outline potential partnerships in Taipei, Tokyo, and Seoul aimed at expanding data resources and accelerating commercialization. The company aims to achieve Medicare reimbursement for its multi-cancer early detection test by the end of 2028.
3mo ago20/20 BioLabs seeks East Asia M&A, JV deals to roll up AI blood test assets
20/20 BioLabs is pursuing M&A, JV, and licensing deals in East Asia to acquire complementary assets like data, labs, and tech platforms. Management met with partners in Taipei, Tokyo, and Seoul following BIO Asia-Taiwan to advance its AI-powered blood test strategy.
3mo ago20/20 BioLabs targets Medicare path as Q2 revenue jumps 30%
20/20 BioLabs, Inc. reported that its second quarter MCED revenue is expected to be its highest to date, rising at least 30% year-over-year. The company is pursuing a strategy to secure Medicare reimbursement for OneTest™ by 2028, relying on a new statutory pathway for FDA-authorized tests. 20/20 BioLabs differentiates its technology through serial biomarker tracking and protein tumor markers, supported by real-world evidence from firefighter screenings.
4mo ago20/20 BioLabs launches monthly investor webinar series starting July 1
20/20 BioLabs announced a monthly investor webinar series starting July 1, 2026, to improve transparency and shareholder communication. The webinars will provide direct access to management and updates on the company's progress. Attendees will receive a promotional discount code for OneTest, and replays will be available on the company's website.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 1 year ago in 20/20 Biolabs is now worth
$ 0.86
Resulting in a loss of
$ 99.14 (99.14%)
Note: Past profits do not guarantee future returns.
